Investor Presentaiton

SAR-Bombesin: A pan-cancer target SAR-Bombesin is a highly targeted pan-cancer theranostic radiopharmaceutical being to identify and select patients for subsequent treatment of their cancers that express GRPr SAR-Bombesin GRP is a receptor that is overexpressed in a number of cancers including prostate, breast, colon, gastric, glioma, pancreatic, small cell lung and non-small cell lung cancer, as well as renal cell cancer 64CU SAR-Bombesin is retained in the tumours while quickly clearing from the pancreas in hormone positive metastatic breast cancer • 75%-100% of prostate cancers express GRPr • 83% of estrogen receptor (ER) positive breast cancers express GRPr 64 Cu/67 CU SAR-Bombesin has potential to treat a range of cancers that express GRPr, including breast and prostate cancers 64CU SAR-Bombesin will initially be investigated as a diagnostic imaging agent for PSMA-negative prostate cancer T = 1 hour T = 4 hours T = 24 hours Efficacy of 64CU SAR Bombesin in a mouse model of prostate cancer Tumour Volume (mm*) 2000- 1500- 1000- 500- -5 0 5 10 15 20 25 30 35 40 45 50 time after injection (days) + Control group 67 CU-SAR-Bombesin treated group 67 Cu SAR-Bombesin has demonstrated an anti-tumour effect in preclinical models of prostate cancer, when compared to the control group CLARITY 2014 ME 17

View entire presentation